COLITIS, ULCERATIVE

This study tests three doses of an experimental drug called MORF-057 against a placebo in 280 adults with moderate to severe ulcerative colitis. The goal is to see if the drug can safely reduce inflammation and bring about remission, meaning less bleeding, more normal bowel movem…

This study tests two different maintenance doses of the drug TEV-48574 given as a shot every 4 weeks in adults with moderate to severe ulcerative colitis or Crohn's disease. Participants must have completed a previous 14-week study of the same drug. The goal is to see if the drug…

This study looks at the long-term safety of the drug ustekinumab in children aged 2 to under 18 who have Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a prior study and shown benefit from the drug. The main goal is to track …

This study tests whether combining two drugs (guselkumab and golimumab) works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 adults who haven't responded well to other advanced treatments will take part. The goal is to see if the co…

This study tests a drug called guselkumab in children aged 2-17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and sores. The goal is to see if the drug can bring about remission—meaning no symptoms and healed gut lining—by week 56. About…

This study tests if dupilumab can help people with moderate to severe ulcerative colitis that has a specific immune marker (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks. The main goal is to see if symptoms and colon inflammation…

This study tests an injected drug called guselkumab for people with moderate to severe ulcerative colitis, a chronic bowel disease. About 418 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goal is to see if the drug can p…

This study tests an experimental drug called SAR443122 in 187 adults with moderate to severe ulcerative colitis. Participants receive either one of three doses of the drug or a placebo for up to 52 weeks. The goal is to see if the drug can reduce symptoms and inflammation, and to…

This study tests a drug called golimumab in 84 children with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (fewer symptoms) within 6 weeks and m…

This study looks at whether acupuncture can reduce disease activity and pain in children with Crohn's disease or ulcerative colitis. About 60 children with mild to moderate symptoms will receive acupuncture alongside their usual medications. Researchers will measure changes in di…

This study looks at whether health education from nurses can improve quality of life and reduce anxiety and depression in people who have a stoma after digestive surgery. About 70 adults with a permanent or long-term ostomy will take part. They will attend workshops and get follo…

This study is the first time GSK4528287, a drug for inflammatory bowel diseases like ulcerative colitis, is given to humans. It involves 48 healthy volunteers who receive a single dose to check for side effects, measure drug levels in the blood, and see how the drug works in the …

This study looks at 672 adults with moderate to severe ulcerative colitis to find the best treatment target. Participants are split into three groups: one aiming for symptom relief only, another adding endoscopic healing, and a third adding both endoscopic and microscopic healing…